Open AccessEffect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease
Author(s) -
Yasir Hasan Siddique,
Wasi Khan,
Ambreen Fatima,
Smita Jyoti,
Saba Khanam,
Falaq Naz,
Rahul Rahul,
Fahad Ali,
Braj Raj Singh,
Alim Hussain Naqvi
Publication year - 2015
Publication title -
disease models and mechanisms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.327
H-Index - 83
eISSN - 1754-8411
pISSN - 1754-8403
DOI - 10.1242/dmm.022145
Subject(s) - bromocriptine , drosophila (subgenus) , transgene , disease , parkinson's disease , genetically modified mouse , biology , medicine , microbiology and biotechnology , endocrinology , genetics , gene , hormone , prolactin
The effect of bromocriptine, a dopamine agonist, administered in the form of bromocriptine alginate nanocomposite (BANC) was studied on Parkinson's disease (PD) model flies. The synthesized BANC was subject to characterization and, at a final concentration of 0.5, 1.0 and 1.5 µM, was mixed in diet. The PD flies were allowed to feed on it for 24 days. A significant dose-dependent delay in the loss of climbing activity and activity pattern was observed in PD flies exposed to 0.5, 1.0 and 1.5 µM BANC. The PD flies exposed to BANC also showed a significant reduction in lipid peroxidation and glutathione-S-transferase activity, and an increase in glutathione content. However, no gross morphological changes were observed in the brains of PD flies compared with controls. The results suggest that BANC is effective in reducing the PD symptoms in these transgenic flies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom